Under $24m settlement with the California Department of Insurance, AbbVie’s nurse ‘ambassadors’ cannot participate in conversations between patients and insurance companies and must disclose that they are paid by the company.
While AbbVie Inc. has successfully warded off patent infringement and antitrust claims, the California Department of Insurance has succeeded in getting it to change its marketing practices for Humira (adalimumab). Although the changes are limited to California, they could impact marketing of the blockbuster drug elsewhere.
The company agreed to revise its practices and pay $24m to settle a suit by the California Insurance Commissioner. The...
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
AbbVie’s migraine ad overstates the drug’s benefit, a problem that is amplified by using a celebrity, the agency says.
The lung cancer drug Krazati from Bristol Myers Squibb’s Mirati Therapeutics drew an FDA ad/promo untitled letter, highlighting the agency's trend of pursuing false or misleading efficacy claims, particularly when data comes from outside approved labeling.
The UK and EU pharma industry associations have defended their respective codes of practice despite alarming study results. Meanwhile, a consultation on proposals to revise the UK code received over 3,500 comments.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
